SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Instagram Outage Disrupts Thousands of U.S. Users 
New York, NY, Nov. 01, 2017 -- Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announced today that an updated buyback program has been unanimously approved by Daxor’s Board of Directors.
The Board of Directors of Daxor has voted to re-authorize the company’s share buyback for an amount of up to 300,000 shares for the next 12 months. The Company formerly had in place a program that authorized up to 250,000 to be repurchased annually. Stated CEO, Michael Feldschuh, “In light of the value that the shares represent at current market prices and management’s philosophy of increasing shareholder value, I welcome this policy by the Board of Directors of the Corporation.”
Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with Volumex, Daxor’s single-use diagnostic kit. For more information regarding BVA and the Daxor BVA-100, visit Daxor’s website at www.Daxor.com.
Daxor contact information: Diane Meegan Corporate Secretary 212-330-8512 [email protected].
